Adenosine N 1 -oxide (ANO) is a potent and highly selective inhibitor of vaccinia virus replication. We examined the impact of ANO on vaccinia virus macromolecular synthesis during synchronous infection of BSC40 cells. Viral DNA replication and viral late protein synthesis were blocked completely by ANO, effects that were attributable to a defect in the expression of viral early genes. Vaccinia virus early proteins were not synthesized in the presence of ANO, even though vaccinia virus early mRNAs were produced. Cellular protein synthesis was unaffected by ANO, and virus infection in the presence of the drug did not elicit the normal shutoff of host protein synthesis. Adenosine N 1 -oxide triphosphate (ANO-TP), the predominant metabolite of the drug in vivo, could substitute for ATP in RNA synthesis by purified vaccinia virus RNA polymerase. ANO-TP could support early transcription by purified virions if dATP was provided as an energy source. ANO-TP did not inhibit early transcription in the presence of ATP. These findings suggest a novel antiviral mechanism whereby incorporation of a modified nucleotide into viral mRNAs might selectively block viral gene expression at the level of translation. We believe that ANO merits consideration as an antipoxvirus drug for topical treatment of molluscum contagiosum in humans.
Adenosine N 1 -oxide (ANO) is a highly selective inhibitor of vaccinia virus replication (22) . ANO and an extensive series of 1-benzyloxy derivatives display a very high therapeutic index against vaccinia virus in cultured VERO cells, as determined by a reduction in cytopathic effect (22, 34) . These compounds were essentially inactive against any other viruses tested in cell culture (which included representative adeno-, flavi-, arena-, alpha-, phlebo-, and retroviruses). ANO and several derivatives also display activity against vaccinia virus in a virus-induced tail pox model in mice (17, 22) . The 1-benzyloxyadenosine derivatives decompose to ANO at ambient temperature and neutral pH, suggesting that they are acting as prodrug forms of ANO (22) . How ANO actually blocks virus replication is unclear.
ANO was initially evaluated for its ability to inhibit the growth of tumor cells in culture (5) . Early studies showed that ANO was metabolized completely by Ehrlich ascites tumor cells within 4 h of drug exposure, predominantly by phosphorylation to ANO monophosphate (ANO-MP) and ANO triphosphate (ANO-TP) but also by reduction to adenosine (10) . At 4 h, the intracellular concentration of ANO-TP was about twice that of ANO-MP; ANO diphosphate was not detected (10) . ANO-TP and ANO-MP were also formed in L1210 leukemia cells exposed to ANO (22) . Adenosine kinase is the enzyme responsible for conversion of ANO to ANO-MP (32) . Resistance of cultured H.Ep.2 cells to growth inhibition by ANO was associated with complete loss of adenosine kinase activity (3) . Apparently, the biological effects of ANO are mediated by one or more of the phosphorylated derivatives. Exposure of Ehrlich ascites cells to 2 mM ANO for several hours resulted in a 50 to 60% inhibition in the incorporation of [ 3 H]thymidine or 32 P into DNA but had no effect on the incorporation of [ 3 H]uridine or 32 P into RNA (10) . A clue to the antiviral action of ANO emerges from the finding that 2Ј deoxyadenosine N 1 -oxide and its 4-tolyl derivative were 30 to 80 times less potent than the corresponding ribo compounds against vaccinia virus in VERO cells (22) . This suggests that ANO may target viral RNA synthesis rather than DNA synthesis. In this light, it is easy to envision how ANO might target vaccinia virus so specifically, i.e., because vaccinia virus has the exceptional feature of encoding a full complement of enzymes responsible for the synthesis and processing of viral mRNAs (23) . It has been suggested that ANO-TP is the biologically active form of the drug (22) . Vaccinia virus encodes a multitude of ATP-utilizing enzymes with known or presumptive roles in viral mRNA metabolism (15) ; ergo, the virus itself provides numerous potential drug targets. These include a multisubunit DNA-dependent RNA polymerase, an early transcription factor with intrinsic DNA-dependent ATPase activity, a poly(A) polymerase, a nucleotide triphosphate (NTP)-dependent RNA helicase, two DNA-dependent ATPases, and two protein kinases (15) .
In the present study, we examined the effects of ANO on vaccinia virus macromolecular synthesis during synchronous infection of cultured cells. A drug-induced defect in the expression of viral early genes caused inhibition of viral DNA replication and late gene expression. Vaccinia virus early proteins were not synthesized in the presence of ANO, even though early mRNAs were produced. ANO had no effect on ongoing host protein synthesis. Apparently, ANO blocked viral gene expression by selectively preventing translation of viral mRNA.
MATERIALS AND METHODS
Cells and virus. BSC40 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum. Vaccinia virus WR was routinely propagated in BSC40 monolayers at 37ЊC. For in vitro transcription experiments, virus particles were purified from infected HeLa cells by sedimentation through a sucrose cushion; this was followed by two rounds of sedimentation in sucrose gradients.
Materials. ANO and ANO-TP were provided by John A. Secrist III, Southern Research Institute, Birmingham, Ala. Stock solutions of ANO in water (5 mg/ml) were stored at Ϫ20ЊC. ANO-TP was dissolved in water, adjusted to pH 7 with NaOH, and stored as a 10 mM stock solution at Ϫ20ЊC. Radiolabeled nucleotides and amino acids were purchased from Amersham. Viral DNA replication. Confluent BSC40 cell monolayers (9.6-cm 2 wells) that had been preincubated for 8 h in medium containing ANO (20 g/ml) were infected with vaccinia virus at a multiplicity of infection (MOI) of 3. The inoculum was removed after 30 min and replaced with drug-containing medium. Control infections were performed without drug preincubation and in the absence of drug postinfection. Cells were harvested at the indicated times postinfection and pelleted in a clinical centrifuge. The cell pellets were resuspended in 10ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-1 M ammonium acetate and subjected to freezing and thawing (30) . Aliquots of the lysates were denatured in alkali and applied to a nylon membrane (ICN BioTrans), using a vacuum slot blot apparatus (30) . The abundance of viral DNA sequences was assayed by hybridizing to the filter a radiolabeled vaccinia virus DNA probe synthesized by the nick translation method from a plasmid DNA template containing the vaccinia virus genomic HindIII H restriction fragment. The hybridized probe was detected by autoradiographic exposure of the filter.
Protein synthesis. Confluent cell monolayers (4.0-cm 2 wells) that had been preincubated with ANO (20 g/ml) for 8 h were infected with vaccinia virus at an MOI of 6. Control infections were performed without drug preincubation. The inocula were removed and replaced with control medium or with drugcontaining medium. At various times postinfection, the medium was removed, and the cells were washed with methionine-free Dulbecco's modified Eagle's medium and then overlaid with fresh medium containing 30 Ci of [ 35 S]methionine per ml (800 Ci/mmol) for 30 min. For cells infected in the presence of the drug, ANO was maintained at a concentration of 20 g/ml. The medium was removed, and the cells were lysed in situ by the addition of 0.15 ml of a solution containing 0.065 M Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 5% ␤-mercaptoethanol, and 10% glycerol. Lysates were stored at Ϫ20ЊC. Samples (25-l aliquots) were heated at 100ЊC for 5 min and then electrophoresed through a 12% polyacrylamide gel containing 0.1% SDS. Radiolabeled polypeptides were visualized by autoradiographic exposure of the dried gel.
Immunoprecipitation of [ 35 S]methionine-labeled polypeptides. Virus infection in the presence or absence of ANO was performed as described above except that an MOI of 20 was used. The cells were pulse-labeled with [ 35 S]methionine at 2 h postinfection. The cells were lysed in buffer containing 2% SDS, 12.5 mM Tris-HCl (pH 7.5), and 100 mM ␤-mercaptoethanol. The lysates were subjected to two cycles of freezing, thawing, and heating at 100ЊC for 5 min. Immunoprecipitation of virus-encoded D1 and D12 proteins was carried out as described previously (26) . Insoluble material was removed by centrifugation. The lysates were incubated with 25 l of Immunoprecipitin (BRL) for 1 h at 4ЊC and then centrifuged. Aliquots (50 l) of the cleared extracts were incubated with 150 l of anti-D1 or anti-D12 serum (1/15 dilution in radioimmunoprecipitation assay buffer [0.1% Triton X-100, 0.1% bovine serum albumin, 0.1 M Tris-HCl {pH 8.0}, 0.14 M NaCl, 0.025% sodium azide]) for 16 h at 4ЊC. Immunoprecipitin (25 l) was added, and the mixtures were incubated for 2.5 h. The immune precipitate was collected by centrifugation and washed twice with 0.5 ml of radioimmunoprecipitation assay buffer and once with 0.5 ml of 0.1 M Tris-HCl (pH 8.0)-0.14 M NaCl-0.025% sodium azide. The pellets were resuspended in 50 l of 0.12 M Tris-HCl (pH 6.8)-2% SDS-2% ␤-mercaptoethanol-20% glycerol. An aliquot (20 l) was heated for 5 min at 100ЊC and then analyzed by SDSpolyacrylamide gel electrophoresis (PAGE). Radiolabeled polypeptides were visualized by autoradiography of the dried gel.
Northern RNA analysis of viral RNA. Confluent BSC40 cell monolayers were infected with vaccinia virus at an MOI of 10 in the presence of cycloheximide (100 g/ml) or ANO (20 g/ml). A control infection without either drug was also performed. Where indicated, cells were preincubated with cycloheximide for 30 min prior to infection and/or with ANO for 8 h prior to infection. The inocula were applied in the presence of the drugs and, after 30 min, removed and replaced with control medium or medium containing ANO or cycloheximide. Total RNA was recovered at 4 h postinfection by lysis in situ with RNAzol B (Cinna/Biotecx). RNA was isolated as specified by the vendor. RNA samples from an equivalent number of cells were prepared for electrophoresis in buffer containing formamide, formaldehyde, and MOPS (morpholinepropanesulfonic acid). Samples were electrophoresed in a 1.2% agarose gel containing formaldehyde. RNA was transferred to a nylon membrane (ICN BioTrans). Viral mRNAs were detected by hybridizing to the membrane a radiolabeled vaccinia virus DNA probe synthesized by nick translation of the genomic HindIII D restriction fragment (25) .
RESULTS
Replication of vaccinia virus is inhibited by ANO. BSC40 cell monolayers were infected with vaccinia virus WR at a low MOI and exposed continuously thereafter to medium containing ANO. Cells were harvested at 24 h postinfection, and the virus yield was determined by titration. Virus replication was inhibited in a concentration-dependent fashion from 0.1 to 25 g of ANO per ml (Fig. 1) . Exposure of uninfected BSC40 cells to the same levels of ANO for 24 h did not affect the integrity of the monolayer, as assessed by light microscopy. Further studies of the effects of ANO on vaccinia virus replication were therefore routinely performed at a drug concentration of 20 g/ml, this being a noncytotoxic dose with maximal antiviral effect. Cytotoxicity was evident after 48 h of exposure to higher concentrations of ANO (Ͼ50 g/ml) by changes in cell shape, from flattened cells to rounded cells, and, after 72 h, by loss of adherence to the growth surface.
The analysis of virus yield from an infection at low MOI did not distinguish whether ANO inhibited virus replication or virus spread. Thus, we examined the effects of ANO under synchronous growth conditions (Fig. 2) . A typical one-step growth curve was obtained for control infections performed in FIG. 1. ANO inhibits vaccinia virus replication in BSC40 cells. Confluent cell monolayers (9.6-cm 2 wells) were infected with vaccinia virus at an MOI of 0.01. The inoculum was removed after 20 min, and cells were overlaid with fresh medium containing ANO at the indicated concentrations. After 24 h, the cells were harvested by scraping and were pelleted in a clinical centrifuge. Cell pellets were washed twice with Dulbecco's modified Eagle's medium to remove residual drug and then resuspended in 1 ml of Dulbecco's modified Eagle's medium and subjected to three cycles of freezing and thawing. Viral yield (PFU) was determined by titration on BSC40 cell monolayers. The effect of the drug is expressed as the ratio of the virus yield (PFU) at a given concentration of the drug to the virus yield in a control infection (no drug). Relative yield is plotted as a function of the logarithm of the drug concentration.
FIG. 2. One-step infection in the presence of ANO. Confluent BSC40 cell monolayers (9.6-cm 2 wells) that had been preincubated for 8 h in medium containing ANO (20 g/ml) were infected with vaccinia virus at an MOI of 3 in the presence of the drug. The inoculum was removed after 30 min and replaced with medium containing ANO (20 g/ml). Control infections were performed without drug preincubation and in the absence of drug postinfection. Cells were harvested at the indicated times postinfection. Virus yield (log PFU) is plotted as a function of time postinfection in the absence of the drug (Control) or in the presence of ANO (ϩANO) (20 g/ml).
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the absence of the drug; infectious progeny were detected as early as 10 h postinfection and continued to accumulate with time, reaching a plateau at 24 to 30 h. The yield at 30 h reflected a burst size of about 200 PFU per cell. Cells that had been preincubated with ANO (20 g/ml) for 8 h were infected in parallel and maintained thereafter in drug-containing medium. In this case, there was no detectable production of infectious progeny above the residua of the inoculum, i.e., the baseline titer at 1 and 4 h postinfection. ANO effect on vaccinia virus DNA replication. Although ANO inhibited vaccinia virus replication, it remained to be determined which intracellular stage(s) of the virus life cycle was affected by the drug. Initial experiments focused on landmark events of viral macromolecular synthesis in synchronously infected cells. The extent of DNA replication was assayed by slot blot hybridization (30) . Control cell lysates prepared at various times postinfection in the absence of the drug were immobilized on membranes and probed with a radiolabeled vaccinia virus genomic DNA fragment. Autoradiographic exposure of the hybridized filter revealed trace levels of viral DNA at 4 h, with obvious amplification of viral sequences by 10 h that continued at later time points (Fig. 3) . Viral DNA sequences did not accumulate over time during infection in the presence of ANO, indicating that the drug prevented vaccinia virus DNA replication (Fig. 3) .
Effect of ANO on viral protein synthesis. The patterns of viral protein synthesis in the presence or absence of ANO were analyzed by pulse-labeling of synchronously infected cells with [ 35 S]methionine over a 12-h time course postinfection. Cell lysates were prepared immediately after the pulse, and the profile of newly synthesized polypeptides was examined by SDS-PAGE (Fig. 4) . The normal temporal pattern of vaccinia virus gene expression (i.e., the appearance of novel early polypeptides at 2 to 4 h postinfection visible against a background of host protein synthesis; transition to the synthesis of distinctive late proteins by 6 h; and shutoff of host protein synthesis, also by 6 to 8 h postinfection, seen by loss of the prominent 45-kDa host polypeptide) was seen in the control infections. Preincubation of BSC40 monolayers in ANO for 8 h prior to infection had no effect on host protein synthesis (Fig.  4 , compare lanes 0). No induction of viral protein synthesis was detected in the presence of drug. Indeed, host protein synthesis continued unabated for at least 12 h postinfection (Fig. 4) . This finding underscored that ANO exposure was not grossly deleterious to cellular metabolism.
ANO inhibits the synthesis of vaccinia virus early proteins. The background of labeled host polypeptides complicated assessment of the drug effects on vaccinia virus early protein synthesis. Therefore, we assayed by immune precipitation the synthesis of specific early viral polypeptides in the presence and in the absence of ANO. Synchronously infected cells were pulse-labeled with [ 35 S]methionine at 2 h postinfection, and lysates were immunoprecipitated with antiserum raised against two early viral proteins, the D1 and D12 subunits of the vaccinia virus mRNA capping enzyme (18, 25, 26) . Pulse-labeled uninfected cells served as a control for the specificity of the sera (Fig. 5) . No labeled proteins from uninfected cells were specifically precipitated by anti-D1 (Fig. 5, lane 2) or anti-D12 serum (Fig. 5, lane 4) above the background contributed by the preimmune sera (Fig. 5, lanes 1 and 3) . From lysates of cells 35 S]methionine as described in Materials and Methods. An uninfected cell monolayer was labeled in parallel. Cell extracts were prepared for immunoprecipitation with antiserum to vaccinia virus proteins D1 (capping enzyme large subunit; lanes 2, 6, and 10) and D12 (capping enzyme small subunit; lanes 4, 8, and 12). Control immunoprecipitations were performed by using preimmune sera from the rabbits that were immunized against the D1 and D12 antigens: pre-D1, lanes 1, 5, and 9; pre-D12, lanes 3, 7, and 11. Immunoprecipitates from uninfected cells (lanes 1 to 4) , infected cells (lanes 5 to 8), and ϩANO infected cells (lanes 9 to 12) were analyzed by SDS-PAGE. An autoradiogram of the gel is shown.
infected with virus in the absence of the drug, the anti-D1 serum specifically precipitated a labeled 95-kDa polypeptide corresponding to the capping enzyme large subunit (Fig. 5,  lane 6) ; the D1 polypeptide was not precipitated by preimmune serum (lane 5). Anti-D12 serum specifically precipitated the 33-kDa capping enzyme small subunit (Fig. 5, lane 8) ; the D12 protein was not precipitated by preimmune serum (Fig. 5, lane  7) . Note that labeled polypeptides of 25 and 35 kDa were precipitated from virus-infected cells by both preimmune and immune sera (Fig. 5, lanes 5 to 8) ; because these species were not detected in precipitates from uninfected cells, we surmise that the 25-and 35-kDa species are virus-encoded early polypeptides against which the preimmune rabbit serum was reactive.
No labeled D1 or D12 polypeptides were recovered in immune precipitates of lysates from cells infected with virus in the presence of ANO (Fig. 5, lanes 10 and 12) . The 25-and 35-kDa immunoreactive early proteins were also absent from all immunoprecipitates of cells infected in the presence of ANO (Fig. 5, lanes 9 to 12) . These results demonstrated that ANO exposure blocked the synthesis of vaccinia virus early proteins. Because early protein synthesis is a prerequisite for viral DNA replication and because late protein synthesis depends on viral DNA synthesis, we can attribute the inhibitory effect of ANO on vaccinia virus replication to a defect in early gene expression.
ANO effect on viral RNA synthesis. To determine whether ANO inhibition of early protein synthesis was caused by an effect on mRNA synthesis, we analyzed by Northern blotting the accumulation of virus-specific transcripts. RNA prepared at 4 h postinfection was probed with a radiolabeled 16-kbp viral HindIII D restriction fragment (Fig. 6) . The D fragment encodes 13 genes; 6 of these are expressed at early times after infection, and 7 genes are expressed at late times (9, 18, 25) . Prior transcriptional mapping studies showed that the D1 and D6 early mRNAs were 2.8 to 2.9 kb in length, the D4 transcript was 3.6 kb, and the D12 early transcript was 1.3 kb. Early transcripts were also synthesized from genes D7 (0.7 kb) and D9 (1.1 kb), but these mRNAs were less abundant than other early mRNAs from the D fragment (18) . We detected several discrete D-fragment transcripts in virus-infected cells (Fig. 6) . The sizes of these transcripts, which were not evident in Northern blots of uninfected BSC40 cells (blots not shown), were consistent with those of the early transcripts described by LeeChen and Niles (18) . Superimposed on the discrete RNAs was a diffuse background signal arising from late transcription that had commenced by 4 h postinfection. This was confirmed by comparison with RNA isolated from cells infected in the presence of cycloheximide. As expected, the steady-state level of most of the early vaccinia virus mRNAs was increased in the presence of cycloheximide (18) , whereas the heterogeneous late transcripts were eliminated (Fig. 6) .
Vaccinia virus early transcripts were detected at 4 h postinfection in the presence of ANO. Heterogeneous late transcripts were not seen; this was in keeping with the ANOinduced block to DNA replication. Clearly, ANO did not block early mRNA synthesis; the steady-state level of early transcripts in cells infected in the presence of ANO (ANOϩ cells) was comparable to that of cells infected in the absence of the drug. The sizes of the early ANOϩ transcripts were indistinguishable from those of the control mRNAs, at least at the level of resolution afforded by agarose gel electrophoresis. Thus, the ANO block to vaccinia virus early protein synthesis did not arise from a wholesale block to early transcription.
The combination of cycloheximide and ANO did not increase the accumulation of most early viral messages above the level seen with ANO alone, with the possible exception of the 0.7-kb transcript-the presumptive D7 mRNA-which is barely detectable during control infections but is especially susceptible to induction by cycloheximide (18) . The cycloheximide effect has been attributed to a failure to synthesize early viral proteins that normally shut off early transcription, e.g., by promoting disassembly of the virus core. Because early proteins were not synthesized in the presence of ANO, we would expect that ANO treatment should essentially mimic the action of cycloheximide so far as preventing the accumulation of whatever viral proteins are involved in shutoff of early transcription. In this light, it is not surprising that cycloheximide did not further increase the transcript levels in ANOϩ cells. The level of viral mRNA level in ANOϩ cells was not as high as that seen in cycloheximide-treated cells in the absence of ANO but was similar to that of cells infected in the absence of any drug treatment.
Effect of ANO-TP on vaccinia virus mRNA synthesis in vitro. Transcription by permeabilized vaccinia virus virions in vitro is generally viewed as faithfully recapitulating vaccinia virus early transcription as it occurs in vivo in the cytoplasm of the infected cell. Given that ANO is converted by mammalian cells to ANO-TP, we considered whether ANO-TP might be used as a substrate during mRNA synthesis by the RNA polymerase packaged within the virus core. Transcription by vaccinia virions, which was measured by the incorporation of [ (Fig. 7) . ANO-TP by itself could not substitute for ATP (Fig. 7) . A low level of transcription was observed at ANO-TP concentrations of Ͼ2 mM. The amount of RNA synthesis at 3 mM ANO-TP was comparable to that at 0.2 mM ATP. Because the preparation of ANO-TP used in these experiments contained residual ATP (3 to 4% ATP versus 96 to 97% ANO-TP), it is likely that transcription at high concentrations of ANO-TP was attributable, at least in part, to ATP contamination. A mixing experiment showed that ANO-TP was not inhibitory to virion transcription in the pres- ence of ATP, e.g., UMP incorporation in the presence of 2 mM ANO-TP plus 2 mM ATP was 93% of that supported by 2 mM ATP alone (data not shown; see also Table 2 below).
To verify that the ANO-TP preparation was capable of supporting RNA synthesis in vitro, we tested its efficacy as a substrate for Escherichia coli RNA polymerase. The in vitro reactions were programmed by a single-strand template and included ATP or ANO-TP at a 1 mM concentration. UMP incorporation was dependent on added ATP; ANO-TP supported RNA synthesis at 60% of the level sustained by ATP (Table 1) .
DNA-dependent RNA polymerase purified from vaccinia virus virions synthesizes RNA nonspecifically from singlestrand DNA templates (2, 37) ; there is no requirement in this reaction for a vaccinia virus promoter or for the vaccinia virus early transcription factor. This activity is referred to as RNA synthesis, to distinguish it from bona fide early transcription carried out by permeabilized virions. Purified vaccinia virus RNA polymerase, like bacterial RNA polymerase, catalyzed RNA synthesis in the presence of 1 mM ANO-TP to the extent of 43% of the level of UMP incorporation at 1 mM ATP (Table 1) . Synthesis increased with ANO-TP concentrations up to 1 mM and plateaued thereafter (Fig. 8) . The apparent K m of purified polymerase for ANO-TP was 0.4 mM, compared with 80 M for ATP (2, 37) . Mixing 1 mM ATP and 1 mM ANO-TP resulted in an intermediate level of synthesis (Table 1) . These results suggested that ANO-TP was used as a substrate by vaccinia virus RNA polymerase, albeit with lower efficiency than ATP.
ANO-TP and the requirement for ATP hydrolysis. The role of ATP during vaccinia virus early transcription is not limited to its use as a substrate for RNA polymerization. Transcription in vitro is coupled at multiple steps to the hydrolysis of ATP to ADP (11, 14, 19, 27, 36) . This is exemplified by the inability of AMPPNP, a nonhydrolyzable ATP analog, to substitute for ATP during mRNA synthesis by permeabilized virions (11) ( Table 2) . Transcription from early promoters in the presence of AMPPNP can be rescued by dATP (12, 35) . dATP did not support transcription by itself (Table 2) ; ANO-TP, which did not support transcription alone, was unable to rescue transcription in the presence of AMPPNP ( Table 2 ), implying that ANO-TP was not able to satisfy the energy requirement for early mRNA synthesis. However, transcription in the presence of ANO-TP could be rescued by dATP (Table 2 ). This result suggested that ANO-TP could be used by the RNA polymerase if an idoneous energy source was present. The level of transcription in the reaction mixture containing ANO-TP plus dATP did not reach those of control reaction mixtures containing ATP alone or ATP plus ANO-TP (Table 2) . Similar findings were made during earlier dATP rescue studies using AMPPNP and ATP␥S (35, 36) .
DISCUSSION
The studies presented above indicate that ANO inhibition of vaccinia virus replication was caused by a translational block to early protein synthesis. This effect was clearly specific for vaccinia virus transcripts, i.e., the translation of cellular mRNAs continued unabated in virus-infected cells in the presence of ANO. Obviously, the viral mRNAs synthesized in ANOϩ cells must be functionally distinct from control transcripts, either because they lack an essential structural feature or because ANO incorporation into the transcript renders the viral mRNAs untranslatable.
ANO-TP did not support transcription by permeabilized virions when included in place of ATP, apparently because ANO-TP did not satisfy the energy requirement characteristic of vaccinia virus mRNA synthesis. However, the ability of ANO-TP to replace ATP during nonspecific synthesis by purified vaccinia virus RNA polymerase and the dATP rescue of virion transcription in the presence of ANO-TP suggested that ANO-TP was a substrate for chain elongation by vaccinia virus RNA polymerase. Most important, virion transcription in vitro was not inhibited by ANO-TP in the presence of ATP. The mixing experiment is likely to reflect conditions prevailing in the ANO-treated cells, i.e., an environment where ATP and ANO-TP are both present. The in vitro results are thus consistent with the finding that vaccinia virus early transcripts were actually made in ANO-treated cells.
How might incorporation of ANO-MP into vaccinia virus early transcripts interfere with their translation? In the standard Watson-Crick base pair, the N-1 atom of the adenine ring makes a hydrogen bond with the N-3 proton of uracil. Oxidation of the N-1 position in ANO precludes formation of a typical A-U base pair. This would be expected to have a major impact on the codon-anticodon interactions between mRNA and tRNA. Even sporadic incorporation of ANO within viral mRNAs might be sufficient to preclude synthesis of full-length viral polypeptides, i.e., only a few defective codons per mRNA molecule could account for the failure to synthesize viral polypeptides in vivo. This model would account for the efficacy of ANO as an antipoxvirus drug by positing that the vaccinia virus transcription machinery utilizes ANO more readily at noncytotoxic drug concentrations than does the host cell RNA polymerase, hence, the lack of ANO effect on host protein synthesis. The same argument might explain why ANO is so specifically active against poxviruses, i.e., that the RNA transcriptases encoded by most RNA viruses do not readily accept ANO as a substrate. Other DNA viruses rely on the host cell transcription system and thus would not be especially sensitive to ANO. Testing the hypothesis that ANO is incorporated into viral early mRNA in vivo mandates the synthesis of radiolabeled ANO and a demonstration that ANO can be recovered from vaccinia virus-specific transcripts. Efforts to synthesize labeled ANO and ANO-TP are in progress.
Our experiments do not exclude the possibility that viral transcripts synthesized in ANOϩ cells lack some modification critical for translation. The obvious candidates are the 5Ј cap and the 3Ј poly(A) tail. We consider it unlikely that ANO prevents polyadenylation; were this the case, the Northern analysis would have demonstrated detectable shortening of the ANOϩ transcripts compared with the control mRNAs. Slight shortening of the poly(A) tail might not have been appreciated at this level of resolution, but there is no reason to expect that this could account for the translational block. It is conceivable that ANO-MP is incorporated into the poly(A) tail by the vaccinia virus poly(A) polymerase, but it is not obvious how an ANO-containing 3Ј tail might prevent translation.
The methylated cap structure facilitates translation of vaccinia virus mRNAs in vitro (24) . How might ANO affect cap formation? We doubt that ANO or its metabolites would affect the transfer of GMP to the 5Ј end of the mRNA to yield the GpppN cap structure, because the guanylyltransferase reaction is extremely specific for GTP as the cap donor and is not inhibited by other NTPs. Cap methylation at the N-7 position of guanine is a potential target for ANO. S-adenosylmethionine is the methyl donor for the vaccinia virus RNA (guanine-7)-methyltransferase. One scenario might be that ANO-TP can serve as a substrate for the S-adenosylmethionine synthetase, thereby generating S-ANO-methionine, which may inhibit the cap methylation reaction. We are unaware of any evidence that ANO-TP is a substrate for S-adenosylmethionine synthetase. Alternatively, ANO might be metabolized to S-ANO-homocysteine by S-adenosylhomocysteine hydrolase, in which case the oxidized derivative of S-adenosylhomocysteine might inhibit vaccinia virus cap methyltransferase. Note that it has been reported that ANO is a weak substrate for S-adenosylhomocysteine hydrolase purified from bovine liver (13) ; whether the N 1 -oxide of S-adenosylhomocysteine inhibits methyltransferases is unknown.
ANO is one of very few antiviral drugs that are truly specific against poxviruses; others include isatin-␤-thiosemicarbazone (IBT), rifampin, and N 1 -isonicotinoyl-N 2 -3-methyl-4-chlorobenzoylhydrazine (IMCBH). The precise basis for IBT action is not clear; the drug causes breakdown of vaccinia virus late mRNAs that results in a cessation of late protein synthesis. Genetic analysis of IBT resistance and IBT dependence suggests that multiple virus-encoded proteins participate in an IBT-regulated pathway of viral RNA turnover (6, 21) . Rifampin has no effect on vaccinia virus RNA metabolism or protein synthesis but inhibits vaccinia virus morphogenesis by interfering with an early stage in the formation of viral membranes. Rifampin acts through a 65-kDa virus-encoded protein, mutations in which confer rifampin resistance (1, 38) . IMCBH inhibits the release of infectious progeny virus particles by preventing the wrapping of intracellular virions by Golgi membranes (28) . IMCBH targets a virus-encoded 37-kDa protein component of the Golgi-derived viral envelope (31) .
ANO works by a unique mechanism, at least as far as specific antipoxvirus drugs are concerned, in that it blocks early gene expression at the level of translation. Vaccinia virus replication is inhibited by other adenosine analogs, but their actions are generally not specific to the poxviruses. 2-O-Methyl adenosine is active against vaccinia virus at relatively high concentrations (5 mM); this analog, like ANO, causes a block to early protein synthesis (29) , but it is not clear whether this occurs at the level of inhibition of early mRNA synthesis or translation. Other adenosine analogs, e.g., neplanocin (4), C-c3Ado (8) , and adenosine dialdehyde (16) , are believed to affect vaccinia virus replication by inhibiting the cellular enzyme S-adenosylhomocysteine hydrolase (20)-this would increase the level of Sadenosylhomocysteine and thereby inhibit the vaccinia virus RNA methyltransferases. Although this is a plausible mechanism, it has not, to our knowledge, been determined whether viral mRNAs are actually produced during vaccinia virus infection in the presence of these drugs.
The classical genetic approach to defining the in vivo target of drug action is to isolate a drug-resistant virus mutant (7) . We attempted to isolate ANO-resistant mutants of vaccinia virus by serial passage of mutagenized virus stocks in the presence of the drug. Our efforts were unsuccessful, perhaps because the drug targets more than one virus-encoded enzyme. Although frustrating from a mechanistic perspective, our failure to encounter ANO resistance under selection pressure has favorable implications for the therapeutic use of ANO.
Clinical interest in poxviruses has been rekindled in the wake of the emergence of molluscum contagiosum as a common, and at times disfiguring, cutaneous manifestation of human immunodeficiency virus infection in humans (33) . The replication and pathogenesis of molluscum contagiosum virus are poorly understood, largely because there is no cell or animal model for cultivation of molluscum contagiosum virus outside the human host. Given that replication strategies are broadly conserved among members of the poxvirus family, any antipoxvirus agents identified through research on vaccinia virus should be considered promising candidates for the treatment of molluscum contagiosum. We believe that clinical evaluation of ANO for topical therapy of molluscum contagiosum infection is therefore warranted.
